U.S.-based multinational biotechnology organization Thermo Fisher Scientific Inc. is reportedly planning to enter into a definitive agreement to purchase Mesa Biotech Inc. for USD 550 million.
Under the agreement, Thermo Fisher Scientific will be paying around USD 450 million in cash, with an additional USD 100 million after the closure of the transaction, following certain milestones and regulatory approvals.
For the uninitiated, Mesa Biotech is a California-headquartered company that focuses on manufacturing and commercializing next-generation rapid molecular diagnostic tests. The organization aims at providing actionable information